Atara reports patient death in cancer treatment study
Atara Biotherapeutics, a South San Francisco-based drug development company with major operations in Thousand Oaks, reported to the U.S. Food and Drug Administration on Feb. 18 that a patient died in one of its Phase 1 trials. The patient, who was being treated at a Memorial Sloan Kettering Cancer Center location in New York, suffered Read More →
Atara reports growing losses, but plenty of cash left
Atara Biotherapeutics continued seeing losses in the third quarter of fiscal year 2021, but has enough cash on hand to remain solvent as it awaits news on its tab-cel therapy treatment in early 2022. Atara, a South San Francisco-based immunotherapy based company with major operations in Westlake Village, reported net losses of $84.7 million in Read More →
Atara losses grew in Q2
Atara Biotherapeutics swallowed more losses in the second quarter of 2021, as the early-stage company hopes for good news for its tab-cel therapy in early 2022. Atara, an immunotherapy biotech company based in South San Francisco with some of its major operations in Thousand Oaks, had a net loss of $83.7 million in the second Read More →
Atara beats estimates with loss in Q1
Atara Biotherapeutics had a net loss of $78.2 million in the first quarter of fiscal year 2021, slightly higher compared than same quarter a year earlier, when the company had a loss of $73.5 million. Despite this, Atara, an immunotherapy biotech company based in South San Francisco with some of its major operations in Thousand Read More →
Amgen CEO again tops list of region’s highest paid execs
Robert Bradway remained the highest paid executive in the Tri-Counties in 2020, but stock options and new faces changed a lot of the names and positions on the list. Bradway, the CEO of Amgen, earned $20.13 million in total compensation in 2020 — 3% more than he earned in 2019, and 8.23% more than in Read More →
Making an ImmPACT: New firm raises $18M to pursue T-cell therapies
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Atara Biotherapeutics raises $175 million
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
